PolyPid
$ 4.59
-0.65%
12 Feb - close price
- Market Cap 76,354,000 USD
- Current Price $ 4.59
- High / Low $ 4.62 / 4.41
- Stock P/E N/A
- Book Value 0.60
- EPS -2.81
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -3.66 %
- 52 Week High 5.12
- 52 Week Low 2.30
About
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Analyst Target Price
$12.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-02-14 | 2023-11-08 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.41 | -0.37 | -0.78 | -0.7 | -1.07 | -1.22 | -1.25 | -1.37 | -3.84 | -3.4 | -10.8 | -8.4 |
| Estimated EPS | -0.33 | -0.52 | -0.55 | -0.82 | -0.88 | -1 | -1.3 | -1.41 | -4.29 | -4.43 | -13.32 | -4.8 |
| Surprise | -0.08 | 0.15 | -0.23 | 0.12 | -0.19 | -0.22 | 0.05 | 0.04 | 0.45 | 1.03 | 2.52 | -3.6 |
| Surprise Percentage | -24.2424% | 28.8462% | -41.8182% | 14.6341% | -21.5909% | -22% | 3.8462% | 2.8369% | 10.4895% | 23.2506% | 18.9189% | -75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PYPD
2026-02-12 12:58:09
PolyPid aims to complete a rolling NDA submission for its novel antibiotic, D-PLEX100, by the end of Q1 2026, targeting the treatment of abdominal infections. While awaiting FDA feedback on their Phase 3 data, the company is actively engaged in advanced discussions for a strategic US partnership to support the drug's commercialization. Positive trial results are bolstering these partnership talks, underscoring the potential of D-PLEX100.
2026-02-12 12:58:09
PolyPid Ltd. shared its Q4 and full-year 2025 financial results, highlighting a pivotal year marked by successful completion of the SHIELD II Phase III trial for D-PLEX100. The company is preparing for a rolling New Drug Application (NDA) submission for D-PLEX100 by the end of Q1 2026 and is in advanced stages of U.S. partnership discussions. They also introduced Kynatrix as their next-generation technology platform, expanding beyond D-PLEX100 into areas like metabolic disease, with an ultra-long-acting GLP-1 Receptor Agonist program in preclinical development.
2026-02-11 23:58:30
PolyPid's recent earnings call highlighted 2026 as a potentially transformative year due to successful Phase III trials for D-PLEX100, a clear FDA path, and ongoing U.S. partnering talks. Despite positive clinical and regulatory progress, the company faces financial pressure with a short cash runway. The future largely depends on securing a commercial partner and bridging the financing gap until D-PLEX100 can generate significant revenue.
2026-02-11 15:58:30
PolyPid (NASDAQ:PYPD) reported Q4 earnings per share of ($0.41), missing consensus estimates by ($0.07). The company's stock traded down 1.9% following the announcement. Despite positive Phase 3 results for D-PLEX100 and plans for an accelerated FDA review, PolyPid's limited cash runway into H2 2026 suggests a near-term need for additional financing or partnership revenue, potentially diluting shareholders.
2026-02-11 14:28:08
PolyPid reported a Q4 2025 loss of $0.41 per share, missing forecasts by 24.24%, yet its stock saw a modest pre-market increase. The company is advancing D-PLEX100 towards an NDA submission by Q1 2026 and is in advanced discussions for U.S. commercial partnerships, anticipating 2026 to be a transformative year. PolyPid also introduced its new Kynatrix technology platform, expanding beyond localized drug delivery to systemic therapeutic needs, including a long-acting GLP-1 receptor agonist program.
2026-02-11 14:28:08
PolyPid's Q4 2025 earnings call highlighted its progress towards a rolling NDA submission for D-PLEX100, targeting prevention of surgical site infections, with FDA positive feedback received. The company is actively pursuing U.S. commercial partnerships and expects a six-month priority review for its NDA. PolyPid reported a net loss of $8.5 million in Q4 2025 and $34.2 million for the full year, with existing cash expected to fund operations into the second half of 2026.
